Skip to content
Dx

ICD-10-CM 2027 diagnosis code

T36.AX5SAdverse effect of fluoroquinolone antibiotics, sequela

✓ Billable / specificPOA exemptRequires 7th characterNot a principal dx

T36.AX5S is a valid, billable ICD-10-CM code for adverse effect of fluoroquinolone antibiotics, sequela. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2026 (effective October 1, 2025). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About T36.AX5S

T36.AX5S is the ICD-10-CM diagnosis code for adverse effect of fluoroquinolone antibiotics, sequela. It belongs to category T36 (poisoning by, adverse effect of and underdosing of systemic antibiotics), block T36-T50 (poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

The 7th character "S" means sequela: use it for complications or conditions that arise as a direct result of the original condition.

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 922 (Other Injury, Poisoning and Toxic Effect Diagnoses with MCC, relative weight 1.6238) and DRG 923 (Other Injury, Poisoning and Toxic Effect Diagnoses without MCC, relative weight 0.9973), in MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It was added in FY2026, effective October 1, 2025.

7th character

Ssequela

Other encounter types for T36.AX5:

Notes that apply from higher levels

Instructions written at a parent level also apply to T36.AX5S.

› From T36 Poisoning by, adverse effect of and underdosing of systemic antibiotics
Excludes1
  • antineoplastic antibiotics (T45.1-)
  • locally applied antibiotic NEC (T49.0)
  • topically used antibiotic for ear, nose and throat (T49.6)
  • topically used antibiotic for eye (T49.5)

Broader instructions also apply from T36-T50 Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances and Chapter 19: Injury, poisoning and certain other consequences of external causes.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2026 (effective 10/1/2025): Added
  • No changes since FY2026.

Common questions about T36.AX5S

Is T36.AX5S billable?

Yes. T36.AX5S is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

What does the "S" at the end of T36.AX5S mean?

It is the 7th character for sequela. Per the official guidelines, use it for complications or conditions that arise as a direct result of the original condition.

Can T36.AX5S be used as a principal diagnosis?

No. It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

Is T36.AX5S a CC or MCC?

No. T36.AX5S is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does T36.AX5S group to?

T36.AX5S is used in the MS-DRG v44.0 logic for MS-DRG 922 (Other Injury, Poisoning and Toxic Effect Diagnoses with MCC) and MS-DRG 923 (Other Injury, Poisoning and Toxic Effect Diagnoses without MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.